Prostate Cancer | Specialty

Blood Test Predicts Resistance to Enzalutamide in mCRPC

June 23rd 2014

It may be possible to predict which men with metastatic castration-resistant prostate cancer will not respond to enzalutamide by using a simple blood test to detect the presence of AR-V7 in circulating tumor cells.

Docetaxel May Cause Intoxication, FDA Warns

June 20th 2014

The FDA has issued a drug safety communication regarding the risk of intoxication with the intravenous ethanol-containing chemotherapy docetaxel.

Dr. Yu Discusses Observation Versus Treatment in Men with Prostate Cancer

June 13th 2014

Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men's treatment decisions after seeing a raise in their PSA levels.

Promising Biomarkers Emerging Across the Spectrum of Prostate Cancer Care

June 12th 2014

Researchers are making progress in identifying biomarkers and developing assays that will help clinicians improve the management of patients with prostate cancer from screening strategies to making therapy choices

Dr. Posadas Discusses Cabozantinib in Prostate Cancer

June 11th 2014

Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer(mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.

Androgen Deprivation Therapy and Cardiovascular Risk in Prostate Cancer

June 11th 2014

Accumulating evidence suggests that androgen deprivation therapy for prostate cancer increases the risk of cardiovascular morbidity and mortality, though not all studies demonstrate an association

Vogelzang Sees Early Chemo Strategy as Landmark Change in Prostate Cancer Therapy

June 10th 2014

Ten years ago, Nicholas J. Vogelzang, MD, helped design a study of docetaxel added to first-line androgen deprivation therapy (ADT) in men with newly diagnosed metastatic, hormone-sensitive prostate cancer.

A Sizable Success: UroPartners Balances Operation of Large Practice with Provision of Singular Care

June 9th 2014

One of the ongoing debates in US politics involves the pros and cons of big government versus small government: Does big automatically equal bureaucracy and groupthink while small inherently fosters individual creativity and enterprise?

Dr. Vogelzang Discusses the Addition of Chemotherapy to ADT in Men With Prostate Cancer

June 9th 2014

Nicholas J. Vogelzang, MD,discusses results from the phase III CHAARTED (E3805) study that examined the addition of chemotherapy to androgen deprivation therapy (ADT) for the treatment of men with newly diagnosed metastatic, hormone-sensitive prostate cancer.

Novel Imaging Techniques for Metastatic Prostate Cancer Advance

June 9th 2014

Improved imaging modalities are needed to help advance treatment of men diagnosed with metastatic prostate cancer, and several novel techniques are under study

2014 NCCN Guideline Updates: Experts Highlight New Recommendations for Clinical Practice

June 6th 2014

At the recent National Comprehensive Cancer Network (NCCN) 19th Annual Conference, experts discussed this year's updates to the NCCN Clinical Practice Guidelines in Oncology. The meeting also included reviews of NCCN Task Force reports on issues in supportive care. We asked eleven NCCN panel members to select the most significant updates and insights presented at the conference.

Radium 223 Option Hinges on Bony Disease Burden in mCRPC

June 5th 2014

As with other new therapies that have been approved in recent years for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), researchers are not entirely certain about how best to fit radium Ra 223 dichloride (Xofigo) into the emerging paradigm

Adding Chemo to ADT Confers Dramatic Survival Gains in Prostate Cancer

June 1st 2014

In what was described as "an almost unprecedented improvement in median survival," the addition of the chemotherapy drug docetaxel to standard hormone therapy prolonged life for men with newly diagnosed metastatic, hormone-sensitive prostate cancer by nearly 14 months.

Dr. Hussain on ETS Gene Fusions as a Predictive Biomarker in Prostate Cancer

May 31st 2014

Maha Hussain, MD, from the University of Michigan Comprehensive Cancer Center, discusses the possibility of ETS gene fusions acting as a predictive biomarker for prostate cancer.

2nd Annual Giants of Cancer Care Awards Honor Leading Researchers

May 30th 2014

The ballots are in, and 16 leading researchers whose discoveries have propelled the field of cancer treatment forward will be honored during the 2014 Giants of Cancer Care award ceremony on May 30 at Riva Restaurant on Navy Pier in Chicago.

Radium-223 Dichloride: A Novel Treatment for CRPC and Symptomatic Bone Metastases

May 29th 2014

The recent approval of several new agents for the treatment of prostate cancer has heralded a new era for managing this condition.

Role of Urologists in Advanced Prostate Cancer Clinics

May 28th 2014

Role of Nurses and Other Care Providers

May 28th 2014

SREs, Risk Stratification, and Agents in Development

May 28th 2014

Treatment Advances in Metastatic CRPC

May 28th 2014